Carl L. Alden, Mayflower Consulting, Wrenceburg, IN, United States
Brian R. Berridge, GlaxoSmithKline Research & Development, King of Prussia, PA, United States
Brad Bolon, GEMpath, Inc., Longmont, CO, United States
Denise I. Bounous, Bristol-Myers Squibb Co., Princeton, NJ, United States
Mark T. Butt, Tox Path Specialists, LLC, Frederick, MD, United States
Russell C. Cattley, Auburn University, Auburn, AL, United States
Robert E. Chapin, Retired, Pfizer Global R&D, Groton, CT, United States
Sandrine F. Chebekoue, University of Montreal, Montreal, QC, Canada
Dianne M. Creasy, Dianne Creasy Consulting, Norfolk, United Kingdom
John M. Cullen, North Carolina State University, Raleigh, NC, United States
Dimitry M. Danilenko, Genentech, South San Francisco, CA, United States
Barbara Davis, Innogenics, Inc., Harvard, MA, United States
Kelly L. Diegel, GlaxoSmithKline Research & Development, King of Prussia, PA, United States
David C. Dorman, North Carolina State University, Raleigh, NC, United States
Richard R. Dubielzig, University of Wisconsin-Madison, Madison, WI, United States
Susan A. Elmore, National Toxicology Program/NIEHS, Research Triangle Park, NC, United States
Suzanne E. Fenton, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States
Duncan C. Ferguson, University of Illinois at Urbana-Champaign, Urbana, IL, United States
George L. Foley, Abbvie, Chicago, IL, United States
Robert H. Garman, Consultants in Veterinary Pathology, Inc., Murrysville, PA, United States
Kathryn E. Gropp, Pfizer Inc., Groton, CT, United States
Diane Gunson, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Gordon C. Hard, Toxicologic Pathology Consulting, Tairua, New Zealand
Jack R. Harkema, Michigan State University, East Lansing, MI, United States
Wanda M. Haschek, University of Illinois at Urbana-Champaign, Urbana, IL, United States
Eugene Herman, National Cancer Institute, Bethesda, MD, United States
Mark J. Hoenerhoff, University of Michigan, Ann Arbor, MI, United States
Evan B. Janovitz, Bristol-Meyer Squibb Company, Princeton, NJ, United States
Kanwar N.M. Khan, Worldwide R&D, Pfizer, Groton, CT, United States
Kannan Krishnan
Risk Sciences International, Ottawa, ON, Canada
University of Montreal, Montreal, QC, Canada
C. Frieke Kuper, TNO, Zeist, The Netherlands
Lois D. Lehman-McKeeman, Bristol-Myers Squibb Company, Princeton, NJ, United States
Xiantang Li, Worldwide R&D, Pfizer, Groton, CT, United States
David E. Malarkey, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States
Robert R. Maronpot, Maronpot Consulting LLC, Raleigh, NC, United States
Kristen J. Nikula, Seventh Wave Laboratories, LLC, Maryland Heights, MO, United States
Ricardo Ochoa, Pre-Clinical Safety, Inc., Niantic, CT, United States
George A. Parker, Charles River Laboratories, Inc., Hillsborough, NC, United States
Lila Ramaiah, Bristol-Myers Squibb Co., New Brunswick, NJ, United States
Colin G. Rousseaux, University of Ottawa, Ottawa, ON, Canada
Daniel G. Rudmann, Flagship Biosciences, Westminster, CO, United States
Christine Ruehl-Fehlert, Bayer AG, Wuppertal, Germany
Stefan U. Ruepp, Bristol-Myers Squibb Company, Princeton, NJ, United States
Kenneth A. Schafer, Vet Path Services, Inc., Mason, OH, United States
John M. Sullivan, Eli Lilly & Company, Indianapolis, IN, United States
Leandro Teixeira, University of Wisconsin-Madison, Madison, WI, United States
John F. Van Vleet†, Purdue University, West Lafayette, IN, United States
Aurore Varela, Charles River Laboratories, Inc., Senneville, QC, Canada
Matthew A. Wallig, University of Illinois at Urbana-Champaign, Urbana, IL, United States
Zbigniew W. Wojcinski, Drug Development Preclinical Services, LLC, Ann Arbor, MI, United States